bearish

Joinn Laboratories (H)

Joinn Laboratories (6127.HK) - Concerns Begin to Arise when the Monkeys Become More Expensive

The article mainly analyzed Joinn about the concerns on its accounting treatment of biological assets, future fair value changes,current business layout, strategy,CXO industry trend and policy impact.

Equity Bottom-Up
184 Views, 01 Dec 2021 09:06
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Shanghai United Imaging Healthcare (688271.CH) - Overvalued; Stock Price Will Return to Rationality
    04 Oct 2022
  • China Healthcare Weekly (Sep.30) - Orthopedics VBP, CGT CDMO, Surgical Robots, Bottom of HKEX
    02 Oct 2022
  • Joinn Laboratories (6127.HK) 22H1 - It's Time to Face Reality Before the Magic of Monkeys Disappears
    29 Sep 2022
  • Joinn Laboratories (6127.HK) - Concerns Begin to Arise when the Monkeys Become More Expensive
    01 Dec 2021
  • Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO
    08 Nov 2021
  • WuXi AppTec (2359.HK/603259.CH) 2021Q3 - Logic Change?
    04 Nov 2021
  • Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns
    01 Nov 2021
  • Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec
    28 Oct 2021
x